Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease

Table 4 Upadacitinib in ulcerative colitis

Ref.	Number of patients	Clinical response at 8 weeks	Clinical remission on maintenance	Major adverse events
Danese et al[56], UC1	319	26%	UC3: 30 mg group: 52%; 15 group: 43%	Nasopharyngitis (5%) and creatine phosphokinase elevation (4%)
UC2	345	34%	UC3: 30 mg group: 52%; 15 group: 43%	Same as above
Sandborn et al[57], phase 2b	250	At 8 weeks clinical remission, 14.3%, 13.5% and 19.6% in 15 mg, 30 mg and 45 mg group	Endoscopic remission: 30.6%, 27% and 35.7% in 15 mg, 30 mg and 45 mg group	One patient herpes zoster, one pulmonary thromboembolism and deep venous thrombosis
Friedberg et al[58], Panaccione et al[59], U-ACTIVATE	44; 369 (15 mg OD: 142 patients and 30 mg OD: 227 patients)	At 4 weeks clinical response: 60% and remission: 77%; not available	At 8 weeks clinical response: 67% and clinical remission: 83%; at 48 weeks, 81% of patients maintained clinical remission in 15 mg OD and 30 mg OD groups; at 96 weeks 47% of patients in 15 mg OD group and 45% patients in 30 mg OD group had endoscopic remission	Acne (23%); treatment emergent adverse events: 15 mg OD: 238.5 events per 100 patient years; 30 mg OD: Group: 233.4 events per 100 patient-years. Most common adverse events were hepatic dysfunction, rise in the CPK and lymphopenia

UC: Ulcerative colitis; OD: Once a day; CPK: Creatine phosphokinase.